Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:45:41 EDT Fri 15 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:SCYX - SCYNEXIS INC - https://www.scynexis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SCYX - Q9.60.73·0.780.80.74-0.0308-4.0435.72611,2100.77  0.77  0.71691.3098  0.56816:10:05May 1115 min RT 2¢

Recent Trades - Last 10 of 1210
Time ETExPriceChangeVolume
16:10:05Q0.74-0.03081
16:04:50Q0.74-0.03081
16:04:22Q0.74-0.03081
16:00:00Q0.74-0.0308659
16:00:00Q0.74-0.03081,000
16:00:00Q0.74-0.03081,293
16:00:00Q0.74-0.0308100
16:00:00Q0.74-0.0308146
16:00:00Q0.74-0.030819
16:00:00Q0.74-0.0308200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-11 16:24U:SCYXNews ReleaseSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-06 21:15U:SCYXNews ReleaseSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-03-31 06:45U:SCYXNews ReleaseSCYNEXIS Announces $40.0 Million Private Placement
2026-03-31 06:40U:SCYXNews ReleaseSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2026-03-04 16:20U:SCYXNews ReleaseSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-02-26 08:23U:SCYXNews ReleaseSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
2026-01-28 08:00U:SCYXNews ReleaseSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
2026-01-21 08:00U:SCYXNews ReleaseSCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
2025-12-22 08:00U:SCYXNews ReleaseSCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
2025-11-19 07:00U:SCYXNews ReleaseSCYNEXIS Completes Transfer of BREXAFEMME(TM) New Drug Application to GSK
2025-11-17 10:15U:SCYXNews ReleaseScynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
2025-11-05 16:20U:SCYXNews ReleaseSCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-15 08:00U:SCYXNews ReleaseSCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
2025-09-30 08:00U:SCYXNews ReleaseSCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
2025-09-04 08:30U:SCYXNews ReleaseSCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
2025-08-25 08:00U:SCYXNews ReleaseSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 - 10, 2025
2025-08-13 16:30U:SCYXNews ReleaseSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-05-28 08:30U:SCYXNews ReleaseSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study